ATEA PHARMACEUTICALS INC (AVIR)
US04683R1068 - Common Stock
ChartMill assigns a Buy % Consensus number of 49% to AVIR. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 3.57. This target is -4.03% below the current price.
AVIR was analyzed by 9 analysts. The buy percentage consensus is at 49. So analysts seem to be rather neutral about AVIR.
In the previous month the buy percentage consensus was at a similar level.
AVIR was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-08-10 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2023-03-16 | JP Morgan | Maintains | Neutral |
| 2023-01-27 | SVB Leerink | Maintains | Market Perform |
| 2023-01-24 | Morgan Stanley | Maintains | Underweight |
| 2022-08-15 | Morgan Stanley | Maintains | Underweight |
| 2022-03-02 | JP Morgan | Maintains | Neutral |
| 2022-03-01 | SVB Leerink | Maintains | Market Perform |
| 2022-02-16 | SVB Leerink | Maintains | Market Perform |
| 2022-01-06 | Morgan Stanley | Downgrade | Equal-Weight -> Underweight |
| 2021-11-18 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2021-10-20 | SVB Leerink | Maintains | Outperform |
| 2021-10-20 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2021-10-05 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2021-09-09 | SVB Leerink | Initiate | Outperform |
| 2021-08-18 | Morgan Stanley | Maintains | Overweight |
| 2021-06-03 | Morgan Stanley | Maintains | Overweight |
| 2021-04-06 | Morgan Stanley | Maintains | Overweight |